|
Phase I/II trial on intraoperative radiotherapy (IORT) in glioblastoma multiforme (INTRAGO). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Carl Zeiss Meditec |
Speakers' Bureau - Carl Zeiss Meditec |
Travel, Accommodations, Expenses - Carl Zeiss Meditec |
|
|
Honoraria - Carl Zeiss Meditec |
Consulting or Advisory Role - Carl Zeiss Meditec |
Speakers' Bureau - Carl Zeiss Meditec |
Research Funding - Carl Zeiss Meditec |
|
|
Honoraria - Carl Zeiss Meditec |
Consulting or Advisory Role - Carl Zeiss Meditec |
Speakers' Bureau - Carl Zeiss Meditec |
Research Funding - Carl Zeiss Meditec |
Travel, Accommodations, Expenses - Carl Zeiss Meditec |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Carl Zeiss Meditec |
Travel, Accommodations, Expenses - Carl Zeiss Meditec |
|
|
Honoraria - Carl Zeiss Meditec; Celgene; Elekta; Ipsen; Lilly; Medtronic; Roche |
Consulting or Advisory Role - Celgene; Elekta |
Research Funding - Carl Zeiss Meditec (Inst); Elekta (Inst); IBA (Inst); Merck KGaA (Inst); opasca (Inst) |
Patents, Royalties, Other Intellectual Property - Co-development of IORT with Carl Zeiss Meditec |
Travel, Accommodations, Expenses - Carl Zeiss Meditec; Celgene; Elekta; Lilly; Roche; Sennewald GmbH |